171 related articles for article (PubMed ID: 33404391)
1. Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities.
Dilley M; Wangberg H; Noone J; Geng B
Allergy Asthma Proc; 2021 Jan; 42(1):78-86. PubMed ID: 33404391
[No Abstract] [Full Text] [Related]
2. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.
Runken MC; Noone JM; Blanchette CM; Zacherle E; Howden R
Am Health Drug Benefits; 2019 Oct; 12(6):294-304. PubMed ID: 31908713
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
[TBL] [Abstract][Full Text] [Related]
4. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States: Data From National Health Care Claims and the US Immunodeficiency Network Registry.
Leung J; Sullivan KE; Perelygina L; Icenogle JP; Fuleihan RL; Lanzieri TM
J Clin Immunol; 2018 Aug; 38(6):717-726. PubMed ID: 30043271
[TBL] [Abstract][Full Text] [Related]
6. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.
Bonagura VR
J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459
[TBL] [Abstract][Full Text] [Related]
7. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.
Patel NC; Torgerson T; Thakar MS; Younger MEM; Sriaroon P; Pozos TC; Buckley RH; Morris D; Vilkama D; Heimall J
J Clin Immunol; 2023 Oct; 43(7):1557-1565. PubMed ID: 37266769
[TBL] [Abstract][Full Text] [Related]
9. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment.
Rider NL; Kutac C; Hajjar J; Scalchunes C; Seeborg FO; Boyle M; Orange JS
J Clin Immunol; 2017 Jul; 37(5):461-475. PubMed ID: 28536745
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Outcomes of Primary Immunodeficiency in Hospitalized Children in the United States.
Rubin Z; Pappalardo A; Schwartz A; Antoon JW
J Allergy Clin Immunol Pract; 2018; 6(5):1705-1710.e1. PubMed ID: 29339125
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.
Wasserman RL; Lumry W; Harris J; Levy R; Stein M; Forbes L; Cunningham-Rundles C; Melamed I; Kobayashi AL; Du W; Kobayashi R
J Clin Immunol; 2016 Aug; 36(6):590-9. PubMed ID: 27324887
[TBL] [Abstract][Full Text] [Related]
14. Performance status and deaths among children registered in Kuwait National Primary ImmunoDeficiency Disorders Registry.
Al-Herz W; Zainal ME; Alenezi HM; Husain K; Alshemmari SH
Asian Pac J Allergy Immunol; 2010; 28(2-3):141-6. PubMed ID: 21038783
[TBL] [Abstract][Full Text] [Related]
15. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
[TBL] [Abstract][Full Text] [Related]
16. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
17. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007.
Kobrynski L; Powell RW; Bowen S
J Clin Immunol; 2014 Nov; 34(8):954-61. PubMed ID: 25257253
[TBL] [Abstract][Full Text] [Related]
19. Why I use subcutaneous immunoglobulin (SCIG).
Shapiro RS
J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
